Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
102.161,19
-0,25%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Johnson and Johnson (JNJ) Johnson and Johnson (JNJ) Notizie

Johnson and Johnson

JNJ
152,06
-0,81 (-0,53%)
01 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/1/202514:00PRNCAJohnson & Johnson champions first-ever Canadian consensus..
23/1/202511:35PRNUSFindings from pivotal nipocalimab Phase 3 study in a broad..
22/1/202523:25EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
22/1/202522:55EDGAR2Form 8-K/A - Current report: [Amend]
22/1/202512:35EDGAR2Form 8-K - Current report
22/1/202512:20BWJohnson & Johnson Reports Q4 and Full-Year 2024 Results
21/1/202514:00PRNUSSPRAVATO® (esketamine) approved in the U.S. as the first and..
17/1/202522:44IHMARKETNEWSU.S. Stocks Move Sharply Higher, Dow Reaches One-Month..
16/1/202515:12PRNCARYBREVANT® associé à une chimiothérapie approuvé au Canada..
16/1/202515:11PRNCARYBREVANT® plus chemotherapy approved in Canada as first and..
15/1/202514:00PRNUSNew Drug Application initiated with U.S. FDA for TAR-200,..
13/1/202523:27EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
13/1/202512:32GLOBEJohnson & Johnson Strengthens Neuroscience Leadership with..
13/1/202512:30BWJohnson & Johnson Strengthens Neuroscience Leadership with..
09/1/202514:04PRNUSNipocalimab granted U.S. FDA Priority Review for the..
08/1/202514:00PRNUSJohnson & Johnson's Posdinemab and Tau Active Immunotherapy..
07/1/202514:00PRNUSRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib)..
02/1/202514:00BWJohnson & Johnson Announces Quarterly Dividend for First..
12/12/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202422:30BWJohnson & Johnson to Participate in the 43rd Annual J.P...
10/12/202414:00BWJohnson & Johnson to Host Investor Conference Call on..
10/12/202401:30PRNUSCARVYKTI® (ciltacabtagene autoleucel) demonstrated..
09/12/202414:00PRNUSWarm autoimmune hemolytic anemia (wAIHA) research presented..
09/12/202401:30PRNUSDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based..
08/12/202418:33PRNUSTECVAYLI® (teclistamab-cqyv) demonstrates potential as..
08/12/202417:21PRNUSDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows..
04/12/202419:25EDGAR2Form 144 - Report of proposed sale of securities
02/12/202414:00PRNUSJohnson & Johnson seeks U.S. FDA approval for first..
22/11/202414:00PRNUSJohnson & Johnson seeks U.S. FDA approval for subcutaneous..
21/11/202422:00PRNCASanté Canada autorise CARVYKTI® (ciltacabtagène autoleucel)..
19/11/202415:02PRNUSJohnson & Johnson to showcase strength of its broad..
18/11/202422:30PRNUSIcotrokinra delivered an industry-leading combination of..
14/11/202416:00PRNUSNipocalimab demonstrates significant clinical improvement in..
13/11/202422:45EDGAR2Form 13F-HR - Quarterly report filed by institutional..
11/11/202422:05PRNUSNipocalimab is the first and only investigational therapy..
08/11/202413:00PRNUSJohnson & Johnson submits applications in the U.S. and EU..
07/11/202414:00PRNUSJohnson & Johnson advances leadership in rheumatic disease..
06/11/202415:23EDGAR2Form 25-NSE - Notification filed by national security..
04/11/202421:11GLOBEEmpower 2024 Delivers Groundbreaking Insights and Innovation..
01/11/202416:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
28/10/202412:30PRNUSTREMFYA® (guselkumab) is the first and only IL-23 inhibitor..
25/10/202414:05PRNUSNew SPECTREM study findings reveal TREMFYA® (guselkumab)..
24/10/202414:00PRNUSJohnson & Johnson highlights innovative neuropsychiatry..
23/10/202422:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22/10/202400:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/10/202423:23EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
18/10/202422:47EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
15/10/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 152,72 Min: 152,055 Max: 153,18
Chiusura: 152,87

La tua Cronologia

NYSE
JNJ
Johnson and Johnson
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci